David Bourget (Western Ontario)
David Chalmers (ANU, NYU)
Rafael De Clercq
Ezio Di Nucci
Jack Alan Reynolds
Learn more about PhilPapers
Topoi 23 (2):145-152 (2004)
It is almost universally acknowledged that risks have to be weighed against benefits, but there are different ways to perform the weighing. In conventional risk analysis, collectivist risk-weighing is the standard. This means that an option is accepted if the sum of all individual benefits outweighs the sum of all individual risks. In practices originating in clinical medicine, such as ethical appraisals of clinical trials, individualist risk-weighing is the standard. This implies a much stricter criterion for risk acceptance, namely that the risk to which each individual is exposed should be outweighed by benefits for that same individual. The different choices of risk-weighing methods in different policy areas seem to have emerged from traditional thought patterns and social relations, rather than from explicit deliberations on possible justifications for the alternative ways to weigh risks against benefits. It is not obvious how the prevalent differences in risk-weighing practices can be reconstructed in terms of consistent underlying principles of preventive health or social priority-setting.
|Keywords||Philosophy Philosophy Philosophy of Science Philosophy of Technology|
|Categories||categorize this paper)|
Setup an account with your affiliations in order to access resources via your University's proxy server
Configure custom proxy (use this if your affiliation does not provide a proxy)
|Through your library|
References found in this work BETA
Tom L. Beauchamp (2009). Principles of Biomedical Ethics. Oxford University Press.
Sven Ove Hansson (2003). Ethical Criteria of Risk Acceptance. Erkenntnis 59 (3):291 - 309.
Alex John London (2001). Equipose and International Human-Subjects Research. Bioethics 15 (4):312–332.
Robert M. Veatch (2002). Indifference of Subjects: An Alternative to Equipoise in Randomized Clinical Trials. Social Philosophy and Policy 19 (2):295-323.
Fred Gifford (1995). Community-Equipoise and the Ethics of Randomized Clinical Trials. Bioethics 9 (2):127–148.
Citations of this work BETA
Christopher Groves (2009). Nanotechnology, Contingency and Finitude. NanoEthics 3 (1):1-16.
Madeleine Hayenhjelm & Jonathan Wolff (2012). The Moral Problem of Risk Impositions: A Survey of the Literature. European Journal of Philosophy 20 (S1):E1-E142.
Erik Malmqvist (2015). Kidney Sales and the Analogy with Dangerous Employment. Health Care Analysis 23 (2):107-121.
Sven Ove Hansson (2007). Hypothetical Retrospection. Ethical Theory and Moral Practice 10 (2):145 - 157.
Sven Ove Hansson (2006). Uncertainty and the Ethics of Clinical Trials. Theoretical Medicine and Bioethics 27 (2):149-167.
Similar books and articles
Douglas MacLean (1982). Quantification, Regulation, and Risk Assessment. PSA: Proceedings of the Biennial Meeting of the Philosophy of Science Association 1982:243 - 260.
Charles Weijer, The Ethical Analysis of Risks and Potential Benefits in Human Subjects Research: History, Theory, and Implications for U.S. Regulation.
Janet Malek (2007). Understanding Risks and Benefits in Research on Reproductive Genetic Technologies. Journal of Medicine and Philosophy 32 (4):339 – 358.
Alan Petersen & Alison Anderson (2007). A Question of Balance or Blind Faith?: Scientists' and Science Policymakers' Representations of the Benefits and Risks of Nanotechnologies. [REVIEW] NanoEthics 1 (3):243-256.
Béatrice Rey (2003). Total and Partial Bivariate Risk Premia: An Extension. Theory and Decision 55 (1):59-69.
Lantz Miller (1998). Filling the Gaps in the Risks Vs. Benefits of Mammalian Adult-Cell Cloning: Taking Bernard Rollin's Philosophy its Next Step. [REVIEW] Journal of Agricultural and Environmental Ethics 11 (1):1-16.
E. Marchant Gary, J. Sylvester Douglas & W. Abbott Kenneth (2008). Risk Management Principles for Nanotechnology. NanoEthics 2 (1).
Gary E. Marchant, Douglas J. Sylvester & Kenneth W. Abbott (2008). Risk Management Principles for Nanotechnology. NanoEthics 2 (1):43-60.
Sven Ove Hansson (2006). Economic (Ir)Rationality in Risk Analysis. Economics and Philosophy 22 (2):231-241.
Annette Rid & David Wendler (2011). A Framework for Risk-Benefit Evaluations in Biomedical Research. Kennedy Institute of Ethics Journal 21 (2):141-179.
Added to index2009-01-28
Total downloads48 ( #83,939 of 1,790,069 )
Recent downloads (6 months)12 ( #68,906 of 1,790,069 )
How can I increase my downloads?